Key Highlights

  • Black Hawk Acquisition shares were up 22.79% at USD 6.60 in pre-market on Friday, November 13, 2026, according to pre-market market data. Calculated arithmetic places the prior close near USD 5.38.
  • Holders backed the combination with Vesicor Therapeutics at an October 13, 2026 meeting, and roughly 2.09 million shares were redeemed for about USD 25.2 million, per a published summary of the filing.
  • The April 2025 agreement valued Vesicor at USD 70 million before the transaction, required Vesicor to raise at least USD 10 million of transaction financing and carried a USD 1 million break-up fee.
  • The latest Quarterly Report showed cash of about USD 12 thousand and a Working Capital Deficit near USD 2.3 million, together with a formal Going Concern qualification.

A Blank-Check Vehicle Moves Without a Dated Announcement

Black Hawk Acquisition (NASDAQ:BKHA), a blank-check company, traded 22.79% higher at USD 6.60 in pre-market on Friday, November 13, 2026. No company announcement explaining the move was located for November 11 to 13. The calculated prior close of about USD 5.38 implies a gain of USD 1.22 a share. Blank-check shares can trade erratically once a vote has passed and the remaining holders are mostly arbitrage funds, and with thin trading a modest order can move the price. Whether the Merger has been completed, and whether the ticker has changed, was not confirmed. The trust figures and the 22.79% move both need checking against the final filings.

Merger Terms, the Shareholder Vote and Redemptions

Black Hawk Acquisition (NASDAQ:BKHA) signed a definitive agreement with Vesicor Therapeutics on April 26, 2025. The plan has Black Hawk re-domiciling as a Delaware corporation, a Subsidiary merging into Vesicor, and the combined company adopting the Vesicor Therapeutics name. All proposals passed at the October 13, 2026 shareholder meeting. Redemptions of about 2.09 million shares withdrew roughly USD 25.2 million from the trust, which implies about USD 12.04 a share. That figure conflicts with a USD 10.05 trust value in another summary, so both numbers are unverified and drawn from automatically generated summaries.

Going Concern Doubt, Financing Lines and a December Deadline

The latest quarterly report for Black Hawk Acquisition (NASDAQ:BKHA) cites cash of about USD 12 thousand, a working capital deficit near USD 2.3 million and substantial doubt about continuing as a going concern. Financing includes USD 1.5 million of convertible notes at USD 1.00 a share and a USD 200 million standby Equity purchase agreement with Meteora, alongside forward purchase and non-redemption agreements. A failure to complete by the December 2026 deadline would force liquidation, according to a published summary. Nasdaq compliance on Market Value of listed securities was regained in August 2026. Dilution from the equity line and a thin float are the main risks.

Where Things Stand

Possibly, but only if the deal completes on schedule and the stock keeps tracking it. No announcement explaining the 22.79% pre-market advance at Black Hawk Acquisition (NASDAQ:BKHA) was located. Shareholders approved the Vesicor merger on October 13, 2026; what remains is completion, the Delaware re-domestication, any ticker change and the funding Vesicor still needs to arrange. Going concern doubt, USD 12 thousand of cash and the December 2026 deadline add risk. Watch for a completion filing, the new trading symbol and the post-merger share count, and check any figure from the summaries against filings. A SPAC share price anchors to trust value only until the merger is completed.